BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,090 filers reported holding BAXTER INTL INC in Q2 2021. The put-call ratio across all filers is 1.03 and the average weighting 0.2%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $1,399,644 | +149.5% | 34,508 | +213.5% | 0.72% | +215.4% |
| Q4 2022 | $561,078 | -95.7% | 11,008 | -95.5% | 0.23% | -94.7% |
| Q3 2022 | $13,201,000 | +128.7% | 245,093 | +172.7% | 4.30% | +112.3% |
| Q2 2022 | $5,772,000 | +186.2% | 89,863 | +258.6% | 2.02% | +265.5% |
| Q2 2021 | $2,017,000 | +99.5% | 25,059 | +99.3% | 0.55% | +85.3% |
| Q3 2020 | $1,011,000 | -72.3% | 12,575 | -70.4% | 0.30% | +49.5% |
| Q2 2020 | $3,654,000 | +27.9% | 42,439 | +24.3% | 0.20% | -77.8% |
| Q4 2019 | $2,856,000 | -45.7% | 34,151 | -49.9% | 0.90% | -61.5% |
| Q3 2018 | $5,257,000 | -11.3% | 68,190 | -15.0% | 2.34% | -9.0% |
| Q2 2018 | $5,924,000 | +173.1% | 80,229 | +140.6% | 2.57% | +217.2% |
| Q1 2018 | $2,169,000 | -33.2% | 33,349 | -33.6% | 0.81% | -18.4% |
| Q4 2017 | $3,248,000 | +149.5% | 50,249 | +142.2% | 0.99% | +152.0% |
| Q3 2017 | $1,302,000 | +117.4% | 20,749 | +109.6% | 0.39% | +133.1% |
| Q2 2017 | $599,000 | +188.0% | 9,900 | +110.6% | 0.17% | +96.5% |
| Q4 2016 | $208,000 | -47.5% | 4,700 | -43.4% | 0.09% | -41.5% |
| Q3 2016 | $396,000 | -56.0% | 8,309 | -58.3% | 0.15% | -51.2% |
| Q2 2016 | $900,000 | -75.3% | 19,909 | -61.8% | 0.30% | -72.0% |
| Q2 2015 | $3,643,000 | -8.3% | 52,100 | -10.2% | 1.08% | -18.1% |
| Q1 2015 | $3,973,000 | – | 58,000 | – | 1.31% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SECTOR GAMMA AS | 713,500 | $49,895,000 | 12.74% |
| Veritas Asset Management LLP | 7,636,450 | $534,017,000 | 7.53% |
| FIRST NEW YORK SECURITIES LLC /NY | 154,158 | $10,780,269,000 | 5.40% |
| Gabalex Capital Management LLC | 200,000 | $14,981,000 | 5.39% |
| Veritas Investment Management LLP | 291,825 | $18,816,000 | 5.32% |
| Tweedy, Browne Co LLC | 2,543,966 | $177,900,000 | 4.91% |
| York Capital Management Global Advisors, LLC | 8,074,375 | $564,641,000 | 4.78% |
| First Fiduciary Investment Counsel, Inc. | 270,675 | $18,928,000 | 4.10% |
| SCHARF INVESTMENTS, LLC | 2,247,225 | $157,148,000 | 4.03% |
| Osher Van de Voorde Investment Management | 96,235 | $6,730,000 | 3.91% |